Undisclosed CAR-T cell therapy / Beijing Imunopharm, Izvarino Pharma - LARVOL DELTA

Production of the CAR-T drug at KFU will be launched for $5.6 million [Google translation] (Pharmamedicine) - "Under the terms of the first agreements, Cygenta will transfer technology to Izvarino Pharma and make a transfer to organize the production of a CAR-T drug in Kazan. In order to conduct CAR-T immunotherapy, a clinic will be provided at KFU. It has the status of a federal clinical center and a license to provide medical care in the oncohematological profile....Izvarino Pharma, at its own expense, is developing a project, reconstructing the purchase of equipment for the CAR-T production site in the KFU building. Capital investments will amount to $5.6 million. Commissioning of production is planned for 2025, and obtaining a license from the Ministry of Industry and Trade - for 2026."

Licensing / partnership • Hematological Malignancies • Oncology